<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121077</url>
  </required_header>
  <id_info>
    <org_study_id>21-10169-BO</org_study_id>
    <nct_id>NCT05121077</nct_id>
  </id_info>
  <brief_title>Interval Versus Continuous Training in LVAD Patients</brief_title>
  <acronym>TrainLVAD</acronym>
  <official_title>A Prospective, Comparative Analysis of Moderate-continuous (MCT) and Interval Training (IT) in LVAD (Left Ventricular Assist Device) Patients With Terminal Heart Failure: Train the LVAD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a left ventricular assist device (LVAD) will be randomized to either a moderate&#xD;
      continuous (MCT, 50-60% of VO2peak) or interval training (IT, 80-90% of VO2peak) group for 6&#xD;
      weeks with 3 sessions per week, lasting for 20 minutes. An additional 10 minutes of&#xD;
      resistance training will be performed in each group. Improvement of VO2peak and quality of&#xD;
      life (KCCQ score) between the groups will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In- and out-patients with left ventricular assist device (LVAD) will be recruited to&#xD;
      participate. On consent to participate, patients will be randomized to either moderate&#xD;
      continuous (MCT) or interval (IT) training. An initial cardiopulmonary exercise test (CPET)&#xD;
      will be performed to assess exercise intensity levels using a ramp protocol. Baseline quality&#xD;
      of life (KCCQ score), echocardiographic and LVAD parameters, lab works, including NTproBNP, a&#xD;
      6min walk distance (6 MWD) will be assessed. Patients will then receive 6 weeks of supervised&#xD;
      training in our facility (3x/week, 30min each). Following these sessions CPET, lab works,&#xD;
      KCCQ assessment, 6 MWD, and echocardiography will be performed to assess improvement of&#xD;
      exercise capacity.&#xD;
&#xD;
      Patients in the MCT group will receive 20min of moderate, continuous bicycle training at an&#xD;
      intensity of 50-60% of VO2peak, the IT group will increase exercise density by increasing the&#xD;
      duration of intense bouts (80-90% of VO2peak) over the weeks. All groups will receive an&#xD;
      additional 10 minutes of resistance training (total exercise time 30 minutes in both groups).&#xD;
      Improvement of VO2peak and quality of life (KCCQ score) between the groups will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to either the MCT or IT training group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of peak oxygen uptake (VO2peak) in cardiopulmonary exercise testing (CPET) [ml/kg/min]</measure>
    <time_frame>6 weeks</time_frame>
    <description>Improvement of VO2peak in CPET after a training period of 6 weeks. CPET will be performed before (t0) and after (t1) the training period. A significant improvement from t0 to t1 is considered to be an increase of at least 2,5ml/kg/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Improvement in quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score. Points range from 0 to 100 in each of four domains. The total score is the average of all domains, with higher values depicting better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Moderate continuous training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continuously exercise at a workload between 50-60% of VO2peak on a bicycle ergometer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interval training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will exercise at a varying workload between 50-60% of VO2peak during recovery and 80-90% of VO2peak during bouts of interval training on a bicycle ergometer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Training</intervention_name>
    <description>2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.</description>
    <arm_group_label>Interval training</arm_group_label>
    <arm_group_label>Moderate continuous training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt;18 years&#xD;
&#xD;
          -  clinically stable LVAD patients with terminal heart failure&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  the mental and physical ability to exercise&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  established contraindications for exercise testing&#xD;
&#xD;
          -  systemic blood stream infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Lüdike, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westdeutsches Herz- und Gefäßzentrum Essen, Klinik für Kardiologie und Angiologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Lüdike, Prof.</last_name>
    <phone>+4920172384878</phone>
    <email>peter.luedike@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Wernhart, Dr.Dr.</last_name>
    <phone>+4920172384878</phone>
    <email>simon.wernhart@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lüdike</last_name>
      <phone>020172387878</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Peter Lüdike</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Exercise capacity</keyword>
  <keyword>VO2peak</keyword>
  <keyword>Interval training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual data can be made available by the principal investigator on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

